pentobarbital will reduce the level or influence of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Keep away from coadministration. Strong or moderate CYP3A inducers may possibly lessen cobimetinib systemic publicity by >eighty% and reduce its efficacy.